Arbutus Biopharma Corporation Common Stock
Veridion Score
BETAMEDIUM CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ABUS moving today?
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ABUS overview
Related filings and maps
Congress activity in ABUS
No receipt-qualified Congressional disclosure is present for ABUS in the cached public ledger.
ABUS contract awards, year to date.
Public federal awards linked to this ticker.
ABUS lobbying filings, year to date.
Registered lobbying filings matched to Arbutus Biopharma Corporation Common Stock.